Hot Stocks For 2018


Global Equities Researchs Trip Chowdhry isn’t the only one defending Tesla Motors (TSLA) today after the upstart automaker missed its own delivery forecasts. Baird’s Ben Kallo and Tyler Frank explain why Tesla’s weakness is a buying opportunity:

Hannibal Hanschke/Reuters

Expect shares to face near-term pressure but remain buyers. Total Q2 deliveries were below our estimate and FY:16 deliveries are expected to be slightly below Teslas previously guided range. That said, Tesla had >5k vehicles in transit at quarter-end, and significantly ramped production, nearly reaching its targeted production rate of ~2k vehicles per week. We would be buyers on any weakness as upcoming catalysts (additional Model III details, cash flow positive, Model X reviews, gigafactory updates) should drive shares higher over the long term.

Hot Stocks For 2018: Sarepta Therapeutics, Inc.(SRPT)


Advisors’ Opinion:

  • [By Chris Lange]

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Tuesday following its presentation at the JPMorgan Healthcare Conference. The companys Duchenne muscular dystrophy (DMD) drug, Exondys 51, generated better than expected sales clocking in at $5.4 million in the fourth quarter. Previously, this DMD treatment was approved by the FDA just as recently as September 2016.

  • [By Ben Levisohn]

    After surveying 30 neurologists, Baird’s Brian Skorney and Neena Bitritto-Garg contend that the Street might be underestimating sales of Sarepta Therapeutics (SRPT) Exondys 51 treatment for patients with Duchenne muscular dystrophy. They explain why:

  • [By Lisa Levin]

    Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were also up, gaining 16 percent to $47.52 following the announcement of positive results in its study for the treatment of Duchenne Muscular Dystrophy.

  • [By Ben Levisohn]

    Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).

  • [By Dan Caplinger]

    Yet some stocks didn’t participate in the rally, instead contending with negative news of their own. Zoe’s Kitchen (NYSE:ZOES), GOL Lineas Aereas Inteligentes (NYSE:GOL), and Sarepta Therapeutics (NASDAQ:SRPT) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Johanna Bennett]

    Will healthinsurers pay for Sarepta Therapeutics (SRPT) Exondys 51?

    Thats a question that several analysts have weighed on today. It appears that payors are still actively evaluating and reevaluating coverage of the Duchenne muscular dystrophy drug Exondys 51.

    Approved by the FDA in September, the drug has met with widespread pushback from insurers like Anthem (ANTM), Humana (HUM) and UnitedHealth Group (UNH) amid concerns about its efficacy. So while Sareptas share price has more than doubled over the past 12 months, it has made a sharp retreat, falling 50% to just under $32 a share since hitting a record high $63.73 a share in late September.


    But Cowen analyst Ritu Baral says the tide maybe turning, arguing that coverage denials wont be permanent.

    As SRPT management and our Neuromuscular Disease panelist indicated to us at our recent Healthcare Conference, payor discussions are continuing regarding Exondys 51 with manageable, increasingly positive feedback. Of the major plans we have seen coverage policies released for, only Anthem (including Blue Cross Blue Shield) had previously denied coverage of Exondys, though patients could petition for coverage via a standard appeal process (see further below). Based on their February Specialty Pharmacy Medical Management Prior Authorization Drug List, it appears Anthem will add Exondys 51 to its prior auth list as of 5/1. We think this is encouraging and indicative of the evolving payor landscape surrounding Exondys 51 and more broadly, DMD. Anthem’s pick-up, together with those such as United, which started coverage on 2/1, support the idea of accelerating new patient starts, suggested by SRPT last week at our Healthcare Conference.


    …But Coverage Denials Persist (For Now), Especially Among Non-Ambulatory Patients. While we think the overwhelming majority of amenable patients will eventually be covered for Exondys 51, we do note several social media anecdote

Hot Stocks For 2018: Fossil Inc.(FOSL)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, NVIDIA (NASDAQ:NVDA) and Fossil Group(NASDAQ:FOSL) attracted heavy investor interest following their quarterly earnings reports.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Fossil Group, Inc. (NASDAQ: FOSL) which rose over 9% to $7.75. The stocks 52-week range is $5.50 to $27.93. Volume was 3 million compared to its average volume of 2 million.

  • [By Paul Ausick]

    Fossil Group Inc. (NASDAQ: FOSL) dropped nearly 25% Wednesday to post a new 52-week low of $13.65 after closing at $18.15 on Tuesday. The stock’s 52-week high is $36.87. Volume was more than 5 times the daily average of around 1.9 million shares. The company missed analysts’ expectations bigly this morning.

  • [By Shah Gilani]

    That’s amazingly close to the definition I’d give the once-trendy watch and accessories purveyor turned dinosaur crap retailer, Fossil Group Inc.(Nasdaq: FOSL).

  • [By Ben Levisohn]

    After running through their scenarios,Boruchow comes up with five losers from Trump’s tax plans: Carters (CRI), Urban Outfitters (URBN), Under Armour (UA), Fossil Group (FOSL) and Gap (GPS). He explains why:

  • [By Nicholas Rossolillo]

    Wearable devices are quickly becoming mainstream technology, with smartwatches and fitness trackers leading the way. You’d never know that based on the performance of traditional watchmaker Fossil Group (NASDAQ:FOSL) as the company is struggling to adapt to the changing times.

Hot Stocks For 2018: iShares Core S&P Mid-Cap (IJH)


Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Lubar & Co., Inc’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Lubar+%26+Co.%2C+Inc

    These are the top 5 holdings of Lubar & Co., IncEnLink Midstream LLC (ENLC) – 1,882,007 shares, 37.97% of the total portfolio. Shares added by 0.40%Hallador Energy Co (HNRG) – 2,788,685 shares, 23.23% of the total portfolio. Vanguard Value ETF – DNQ (VTV) – 77,126 shares, 7.65% of the total portfolio. iShares Core S&P Mid-Cap (IJH) – 38,400 shares, 6.84% of the total portfolio. New PositionVanguard Mid-Cap Value ETF – DNQ (VOE) – 61,550 shares, 6.52% of the tota

Leave a Reply

Your email address will not be published.